Marked occipital hypometabolism on FDG-PET in patients with idiopathic RBD may predict Parkinson’s disease
Objective: In the present study, we tried to elucidate if the occipital hypometabolism detected by [(18) F]-fluoro-d-glucose (FDG) positron emission tomography (PET) scan in patients with idiopathic…Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia
Objective: To examine the clinical profile of nelotanserin, a novel agent in development for the treatment of Lewy body dementia. Background: Although not FDA-approved for…Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…Alpha-synuclein aggregates of cardiac sympathetic nerves in synucleinopathies and in neurologically unimpaired subjects. Correlation with sympathetic denervation
Objective: To study the cardiac sympathetic innervation and its relationship with the incidence of alpha-synuclein deposits in heart tissue of synucleinopathies and asymptomatic control patients.…Identification of Usp8 as a toxicity modifying deubiquitinase for α-synuclein
Objective: To study whether ubiquitination in Lewy bodies is directly relevant to α-synuclein turnover and Parkinson's pathogenesis. Background: In Parkinson's disease, misfolded α-synuclein accumulates, often…Toward a new biomarker on Parkinson’s disease: Study of alpha synuclein on upper enteric system by endoscopy
Objective: The aim of our study was to investigate the alpha synuclein deposition at the enteric nerve system on patient with Parkinson's disease and provide…Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker
Objective: We aimed to investigate the utility of alpha-synuclein (α-SYN) immunoreactivity from gastric and colonic mucosal tissues obtained by routine endoscopy to detect Parkinson's disease…Protein levels of SV2A and VGLUT1 in brain tissue from patients with Parkinson’s disease, dementia with Lewy bodies and Alzheimer’s disease
Objective: The objective of this study was to investigate whether SV2A and/or VGLUT1 are suitable as markers for synaptic degeneration in neurodegenerative disorders and could…Novel PET Tracers of alpha-synuclein for the diagnosis of Parkinson’s disease
Objective: The aim of our project is to develop small molecular weight compounds (Morphomers™) which bind selectively to alpha-synuclein (aSyn) aggregates, in order to generate…Targeted over-expression with AAV-mediated human α-synuclein in a rat model of Parkinson’s disease – Validation of novel fine motor functional effects
Objective: Targeted over-expression of human α-synuclein using viral-vector mediated gene delivery into the substantia nigra of rats and non-human primates has been reported to lead…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »